Skip to main content
S 3116 116th Congress Senate

Ending the Diagnostic Odyssey Act of 2019

Official title: A bill to enable States to better provide access to whole genome sequencing clinical services for certain undiagnosed children under the Medicaid program, and for other purposes.

Introduced: March 5, 2020 Introduced by: Collins, Susan M. Republican · Maine See on congress.gov
Health Adoption and foster careCell biology and embryologyChild healthEmergency medical services and trauma care
More subjectsShow fewer subjects
GeneticsHealth care costs and insuranceHealth care coverage and accessHealth care qualityHealth programs administration and fundingHealth technology, devices, suppliesHospital careMedicaidMedical tests and diagnostic methodsState and local government operations
Sign in to write a letter Sign in to watch
This bill died when the 116th Congress ended
It never became law before the 116th Congress (2019–2020) adjourned, and bills don't carry over to the next Congress. It would have to be reintroduced. You can still save it for reference, but it won't receive updates.
 Everywhere this bill has been 2 steps
Introduced
In committee
Reported out
Passed House
Passed Senate
To President
Became law
Dec 19, 2019
Read twice and referred to the Committee on Finance. (Sponsor introductory remarks on measure: CR S7211)
Dec 19, 2019
Introduced in Senate
 Ask about this bill AI · grounded in the bill text

Have a question about what this bill does? Ask in plain English; the answer is drawn from the bill's actual text and official record, and it'll tell you when something isn't in the text rather than guess.

AI answers can be imperfect; always confirm against the full bill text.

 Latest action December 19, 2019

Read twice and referred to the Committee on Finance. (Sponsor introductory remarks on measure: CR S7211)

 Plain-English summary Congressional Research Service

Ending the Diagnostic Odyssey Act of 2019

This bill allows state Medicaid programs to cover whole genome sequencing services for certain individuals.

Specifically, states may cover such services for individuals under the age of 21 (or a lower age, if the state chooses) and for former foster youth under the age of 26 who (1) have been referred or admitted to an intensive care unit or seen by a medical specialist for a suspected genetic or undiagnosed disease, or (2) are suspected by a medical specialist to have a neonatal- or pediatric-onset genetic disease.

The Centers for Medicare & Medicaid Services may award grants to assist states in developing plans to cover such services.

 Related & companion bills 2
  • HR 4393 Related bill Advancing Access to Precision Medicine Act
  • HR 4144 Related bill Ending the Diagnostic Odyssey Act of 2019
 Bill text 1 version

Source documents hosted by congress.gov.

 Committees of jurisdiction 1
 Cosponsors 2
All 2 Democratic 1
D
Smith, Tina
Minnesota · Mar 5, 2020
McSally, Martha
· Dec 19, 2019
Cite this page click to expand
APA
U.S. Congress. (2026). S. 3116: Ending the Diagnostic Odyssey Act of 2019. 116th Congress. Open America. https://openamerica.io/bill/116-S-3116/
MLA
"S. 3116: Ending the Diagnostic Odyssey Act of 2019." 116th Congress, 2026, Open America, https://openamerica.io/bill/116-S-3116/.
Bluebook (legal)
S. 3116, 116th Cong. (2026), https://openamerica.io/bill/116-S-3116/.
Markdown link
[S. 3116: Ending the Diagnostic Odyssey Act of 2019](https://openamerica.io/bill/116-S-3116/)
Report a problem